Google
 

Tuesday, July 22, 2008

Persistent Pulmonary Hypertension of the Newborn

Persistent pulmonary hypertension of the newborn (PPHN) occurs in an estimated 1 or 2 infants per 1000 live births and is associated with substantial morbidity and mortality. Despite treatment, 10 to 20 percent of affected infants will not survive. Newborns with PPHN are typically full-term or near-term infants without associated congenital anomalies who present shortly after birth with severe respiratory failure requiring intubation and mechanical ventilation. This disruption of the normal fetal-to-neonatal circulatory transition is characterized by postnatal persistence of elevated pulmonary vascular resistance, resulting in right-toleft shunting of blood through fetal channels (the patent ductus arteriosus, foramen ovale, or both), diminished pulmonary blood flow, and profound hypoxemia.
Paxil is a popular antidepressant that has a number of distressing and dangerous side effect, birth defect, pregnancy risks, birth injuries, and may even cause death. Dangers of persistent primary hypertension in newborns also called PPHN.
Even though Paxil is used mainly to treat depression, many doctors use it to treat panic disorders, anxiety, and post traumatic stress disorder in almost 17 million people around the world. Unfortunately, the Food and Drug Administration advised doctors that prescribing Paxil to children and teenagers could significantly increase the likelihood of violence and suicidal tendencies.Paxil Attorneys California is one of legal specialist about that.
It is important to replicate these findings in other studies. In addition, further research should
assess the relationship of different types and dosages of SSRIs with PPHN and with milder respiratory complications in newborns. Studies should also be undertaken to investigate whether there is any association between SSRIs and PPHN in the offspring of women who discontinue SSRI use late in pregnancy. Furthermore, to better identify patients who may be at risk, investigations should explore interactions between environmental and genetic factors, the latter including polymorphisms affecting the production or regulation of enzymes involved in the metabolism of SSRIs, as well as mutations related to PPHN.http://www.pphnlawyers.com/